A modest but real gain in knee comfort, stiffness and movement range, mostly in early joint wear and in active adults whose knees ache after loading. No evidence that cartilage is rebuilt or that future mobility is preserved. Most testing is funded by the sellers. Low cost, low risk, an add-on to training with a clear stopping rule. (Full Review)
| Marker | Target | Why |
|---|---|---|
| hs-CRP | < 0.5 mg/L | Systemic inflammatory background against which joint change is judged |
| 25-hydroxyvitamin D | 40–60 ng/mL (100–150 nmol/L) | Deficiency independently worsens joint pain and muscle function, confounding any response |
| Urinary CTX-II | No established target; track change from the individual's own baseline | Direct readout of cartilage breakdown, the one marker plausibly moved by this compound |
| ESR | < 15 mm/h (women), < 10 mm/h (men) | Distinguishes ordinary wear-related joint pain from inflammatory arthritis needing different treatment |
| Serum anti-type II collagen antibodies | No established target; presence rather than level is what matters | Baseline positivity predicted response in a dose-ranging rheumatology trial of oral collagen |
| Complete blood count with differential | Within standard reference range; eosinophils < 500 cells/µL | Screens for the allergic response that is the compound's only real acute hazard |
Cadence: Symptom scoring weekly; formal reassessment at 8 weeks, again at 12 weeks, then every 6 to 12 months on continued use. Laboratory work needs no routine repetition: inflammatory markers are rechecked at 12 weeks only if the baseline was raised, and vitamin D annually. Complete blood count at baseline only unless symptoms appear.